December 15, 2022 03:53 PM ESTUpdated 04:35 PM
R&D

De­bat­ing the p-val­ues be­hind Mod­er­na's $16B mar­ket-cap gain

Jared Whitlock

Features Editor

On Tues­day, Mod­er­na and Mer­ck re­port­ed what looked like one of the most ex­cit­ing pieces of bio­phar­ma news of the year: Mod­er­na’s mR­NA vac­cine …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times